(0.73%) 5 119.50 points
(0.11%) 38 332 points
(1.03%) 17 749 points
(0.72%) $84.17
(-2.63%) $1.595
(0.60%) $2 356.60
(1.27%) $27.70
(1.18%) $931.40
(0.04%) $0.932
(0.10%) $10.96
(0.05%) $0.800
(-0.22%) $91.97
Live Chart Being Loaded With Signals
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States...
Stats | |
---|---|
Today's Volume | 499 002 |
Average Volume | 0.00 |
Market Cap | 64 151.00 |
EPS | $-0.000960 ( 2022-12-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0100 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-04-25 | Knutson Gregory | Buy | 2 500 000 | Common Stock |
2022-03-18 | Knutson Gregory | Buy | 25 000 000 | Common Stock |
2022-02-24 | Knutson Gregory | Buy | 12 500 000 | Warrant |
2022-02-24 | Knutson Gregory | Buy | 12 500 000 | Convertible promissory Note (right to buy) |
2021-03-23 | Murphy William P Jr | Buy | 7 518 797 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 99 transactions |
Buy: 237 671 429 | Sell: 625 000 |
U.S. Stem Cell, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
U.S. Stem Cell, Inc. Financials
Annual | 2022 |
Revenue: | $82 049.00 |
Gross Profit: | $58 282.00 (71.03 %) |
EPS: | $-0.00560 |
FY | 2022 |
Revenue: | $82 049.00 |
Gross Profit: | $58 282.00 (71.03 %) |
EPS: | $-0.00560 |
FY | 2021 |
Revenue: | $200 749 |
Gross Profit: | $148 719 (74.08 %) |
EPS: | $-0.00800 |
FY | 2020 |
Revenue: | $277 087 |
Gross Profit: | $212 970 (76.86 %) |
EPS: | $-0.00673 |
Financial Reports:
No articles found.
U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators